X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/17/2864299/29446/en/BioCryst-Announces-Approval-of-ORLADEYO-berotralstat-by-the-Brazilian-Health-Regulatory-Agency.html
https://www.globenewswire.com//news-release/2024/02/23/2834384/29446/en/BioCryst-Presents-New-Real-world-Data-Showing-Rapid-Substantial-and-Sustained-HAE-Attack-Rate-Reductions-After-Beginning-ORLADEYO-berotralstat-Treatment.html
https://www.globenewswire.com//news-release/2024/02/05/2823391/29446/en/BioCryst-to-Present-New-ORLADEYO-berotralstat-Real-world-Data-at-2024-American-Academy-of-Allergy-Asthma-Immunology-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/01/05/2804867/29446/en/BioCryst-Announces-Preliminary-Full-Year-2023-ORLADEYO-berotralstat-Net-Revenue-of-325-Million-Provides-2024-Guidance-and-Accelerated-Path-to-Profitability.html
https://www.globenewswire.com//news-release/2023/12/19/2798411/29446/en/BioCryst-Announces-Publication-of-Data-from-Open-label-Extension-of-the-APeX-2-Pivotal-Trial-of-ORLADEYO-berotralstat.html
https://www.globenewswire.com//news-release/2023/11/29/2787603/29446/en/BioCryst-Announces-Approval-of-ORLADEYO-berotralstat-by-the-National-Administration-of-Drugs-Foods-and-Medical-Devices-ANMAT-in-Argentina.html
https://www.globenewswire.com//news-release/2023/11/10/2778192/29446/en/BioCryst-Presents-New-Real-world-Data-Showing-Reduced-Attack-Rates-in-Patients-with-HAE-with-Normal-C1-inhibitor-Following-Long-term-Treatment-with-ORLADEYO-berotralstat.html
https://www.globenewswire.com//news-release/2023/10/27/2768280/29446/en/BioCryst-to-Present-New-ORLADEYO-berotralstat-Data-at-Annual-Scientific-Meeting-of-American-College-of-Allergy-Asthma-Immunology.html
https://www.globenewswire.com//news-release/2023/09/18/2744635/29446/en/INESSS-Recommends-Public-Reimbursement-for-BioCryst-s-ORLADEYO-berotralstat-for-the-Prevention-of-Attacks-for-Hereditary-Angioedema-Patients-in-Qu%C3%A9bec.html
https://www.globenewswire.com/news-release/2023/07/19/2707155/29446/en/BioCryst-Selects-Er-Kim-Pharmaceuticals-as-Commercial-Partner-for-ORLADEYO-berotralstat-in-Turkey.html
https://www.globenewswire.com/news-release/2023/05/22/2673216/29446/en/BioCryst-Announces-Approval-of-ORLADEYO-berotralstat-by-the-Public-Health-Institute-of-Chile.html
https://www.globenewswire.com/news-release/2023/04/27/2656138/29446/en/BioCryst-Presents-New-Long-term-Data-Demonstrating-Consistently-High-Attack-free-Status-Among-Hereditary-Angioedema-Patients-with-ORLADEYO-berotralstat.html
https://www.globenewswire.com/news-release/2023/02/24/2615129/29446/en/BioCryst-Presents-New-Long-term-and-Real-world-Data-Demonstrating-Sustained-Reductions-in-Hereditary-Angioedema-Attack-Rates-and-Improvement-in-Quality-of-Life-with-ORLADEYO-berotr.html
https://www.globenewswire.com/news-release/2023/02/03/2601218/29446/en/BioCryst-to-Present-New-ORLADEYO-berotralstat-Data-at-2023-American-Academy-of-Allergy-Asthma-Immunology-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/01/26/2595906/29446/en/BioCryst-Begins-Enrollment-in-Pivotal-APeX-P-Trial-Evaluating-ORLADEYO-berotralstat-in-Pediatric-Patients-with-Hereditary-Angioedema.html
https://www.globenewswire.com/news-release/2023/01/09/2585065/29446/en/BioCryst-Announces-Preliminary-Full-Year-2022-ORLADEYO-berotralstat-Net-Revenue-and-Provides-Full-Year-2023-ORLADEYO-Net-Revenue-Guidance.html
https://www.globenewswire.com/news-release/2022/11/28/2563010/29446/en/BioCryst-Announces-Approval-of-ORLADEYO-berotralstat-by-the-Israeli-Ministry-of-Health.html
https://www.globenewswire.com/news-release/2022/10/24/2539804/29446/en/BioCryst-to-Present-New-ORLADEYO-berotralstat-Data-at-Annual-Scientific-Meeting-of-American-College-of-Allergy-Asthma-Immunology.html
https://www.globenewswire.com/news-release/2022/08/18/2500664/29446/en/BioCryst-Announces-Approval-of-ORLADEYO-berotralstat-in-Saudi-Arabia.html
http://www.pharmafile.com/news/670706/long-term-impact-prophylactic-orladeyo-hereditary-angioedema
https://www.globenewswire.com/news-release/2022/06/22/2466946/29446/en/BioCryst-Announces-ORLADEYO-berotralstat-Data-to-be-Presented-at-European-Academy-of-Allergy-and-Clinical-Immunology-EAACI-Hybrid-Congress-2022.html
https://www.globenewswire.com/news-release/2022/06/07/2457838/29446/en/BioCryst-Announces-Approval-of-ORLADEYO-berotralstat-by-Swissmedic.html
https://www.globenewswire.com/news-release/2022/06/06/2456568/29446/en/BioCryst-Announces-Health-Canada-has-Authorized-ORLADEYO-berotralstat-the-Only-Oral-Treatment-for-the-Prevention-of-Hereditary-Angioedema-Attacks.html
https://www.globenewswire.com/news-release/2022/02/24/2391222/29446/en/BioCryst-Presents-New-Data-Demonstrating-Sustained-Reductions-in-Attack-Rates-and-Improvement-in-Quality-of-Life-Among-HAE-Patients-Following-Long-Term-Treatment-with-ORLADEYO-bero.html
https://www.globenewswire.com/news-release/2022/02/01/2376859/29446/en/BioCryst-to-Present-New-ORLADEYO-berotralstat-Data-at-2022-American-Academy-of-Allergy-Asthma-Immunology-Annual-Meeting.html
https://www.globenewswire.com/news-release/2022/01/10/2363790/29446/en/BioCryst-Announces-Preliminary-Full-Year-2021-ORLADEYO-berotralstat-Net-Revenue-and-Provides-Full-Year-2022-ORLADEYO-Net-Revenue-and-Peak-Sales-Guidance.html
https://www.globenewswire.com/news-release/2021/10/26/2320478/29446/en/BioCryst-to-Present-New-ORLADEYO-berotralstat-Data-at-Annual-Scientific-Meeting-of-American-College-of-Allergy-Asthma-Immunology.html
https://www.globenewswire.com/news-release/2021/09/16/2298040/29446/en/NICE-Recommends-BioCryst-s-ORLADEYO-berotralstat-the-First-Oral-Once-daily-Therapy-to-Prevent-Attacks-in-HAE-Patients-in-the-UK.html
https://www.pharmatimes.com/news/biocrysts_hae_med_orladeyo_wins_nice_nod_1377682
https://www.globenewswire.com/news-release/2021/09/09/2294151/29446/en/BioCryst-Announces-Approval-of-ORLADEYO-berotralstat-in-United-Arab-Emirates.html
https://www.globenewswire.com/news-release/2021/08/25/2286640/29446/en/BioCryst-Announces-Acceptance-of-Regulatory-Applications-for-ORLADEYO-berotralstat-by-Health-Canada-and-Swissmedic.html
https://www.globenewswire.com/news-release/2021/07/10/2260805/29446/en/BioCryst-Reports-96-week-Data-from-APeX-2-Showing-ORLADEYO-berotralstat-Reduced-HAE-Attack-Rate-by-80-Percent-from-Baseline.html
https://www.globenewswire.com/news-release/2021/07/01/2256852/29446/en/ORLADEYO-berotralstat-Data-to-be-Presented-at-European-Academy-of-Allergy-and-Clinical-Immunology-EAACI-Hybrid-Congress.html
https://www.globenewswire.com/news-release/2021/06/16/2248063/29446/en/BioCryst-Announces-Acceptance-and-Accelerated-Review-of-the-ORLADEYO-berotralstat-Marketing-Application-by-the-Israeli-Ministry-of-Health.html
https://www.biospectrumasia.com/news/25/17989/japanese-nhi-price-listing-triggers-15-m-milestone-payment-to-biocryst.html
https://www.globenewswire.com/fr/news-release/2021/04/14/2209965/0/en/BioCryst-Announces-Approval-of-Japanese-NHI-Price-Listing-of-ORLADEYO-berotralstat-for-Prophylactic-Treatment-of-Hereditary-Angioedema.html
https://www.globenewswire.com/news-release/2021/03/11/2191410/0/en/Early-Access-to-BioCryst-s-Berotralstat-Granted-for-HAE-Patients-in-France.html#:~:text=Early%20Access%20to%20BioCryst's%20Berotralstat%20Granted%20for%20HAE%20Patients%20in%20France,-Email%20Print%20Friendly&text=March%2011%2C%202021%2008%3A30,Source%3A%20BioCryst%20Pharmaceuticals%2C%20Inc.&text=This%20cohort%20ATU%20allows%20patients,the%20European%20Commmission%20(EC).
https://www.globenewswire.com/news-release/2021/03/02/2185129/0/en/BioCryst-Submits-Marketing-Authorization-Application-for-UK-Approval-of-ORLADEYO-berotralstat-an-Oral-Once-daily-Therapy-to-Prevent-Attacks-in-Patients-with-Hereditary-Angioedema.html
http://www.pharmatimes.com/news/evrysdi_leads_latest_chmp_recommendations_1364324
https://www.raps.org/news-and-articles/news-articles/2021/2/chmps-february-recommendations-evrysdi-jemperli-an
https://www.globenewswire.com/news-release/2021/02/25/2182982/0/en/BioCryst-Receives-Positive-CHMP-Opinion-for-ORLADEYO-berotralstat-an-Oral-Once-daily-Therapy-to-Prevent-Attacks-in-Patients-with-Hereditary-Angioedema.html
https://www.globenewswire.com/news-release/2020/11/30/2136368/0/en/Allergy-Publishes-Results-from-BioCryst-s-APeX-J-Trial-of-Oral-Once-Daily-Berotralstat-for-the-Prevention-of-HAE-Attacks.html
https://www.globenewswire.com/news-release/2020/11/13/2126393/0/en/BioCryst-Presents-Data-Showing-Sustained-Attack-Rate-Reductions-Improved-Patient-Satisfaction-and-Quality-of-Life-for-HAE-Patients-Taking-Berotralstat-in-APeX-2-Trial.html
https://www.globenewswire.com/news-release/2020/10/30/2117755/0/en/MHRA-Grants-HAE-Patients-Early-Access-to-BioCryst-s-Berotralstat-in-United-Kingdom.html#:~:text=Under%20the%20EAMS%2C%20hereditary%20angioedema,the%20European%20Commission%20(EC).
https://www.globenewswire.com/news-release/2020/05/05/2027388/0/en/New-Composition-of-Matter-Patent-Allowance-Extends-Protection-for-Berotralstat-in-U-S-Market-by-Four-Years-to-2039.html
https://www.globenewswire.com/news-release/2020/03/30/2008205/0/en/European-Medicines-Agency-Validates-Marketing-Authorization-Application-for-Oral-Once-Daily-Berotralstat-BCX7353-to-Prevent-HAE-Attacks.html
http://www.globenewswire.com/news-release/2020/03/16/2000947/0/en/BEROTRALSTAT-BCX7353-SIGNIFICANTLY-REDUCED-USE-OF-ACUTE-ON-DEMAND-MEDICINE-IN-HAE-PATIENTS-IN-APEX-2.html
https://www.globenewswire.com/news-release/2020/02/18/1986123/0/en/FDA-Accepts-BioCryst-s-NDA-for-Oral-Once-Daily-Berotralstat-BCX7353-to-Prevent-HAE-Attacks.html
Market Place
Share 
